Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FBB Biomed has developed minimally invasive blood tests that use proprietary RNA signatures and machine learning to differentiate between specific neurologic diseases. Their products are designed to improve differential diagnosis and therapy monitoring. The company has moved from research to commercial by signing agreements with CLIA & CAP-certified labs to offer research-use-only tests. They have also filed patents related to their methods and presented at major neurology summits. Their COVID‑19 blood test prototype is ready for clinical trials aiming at FDA Emergency Use Authorization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on FBB Solution.